For instance, Avacopan, a NAM for C5aR, was approved to treat ANCA-associated vasculitis, which is an autoimmune disease, by inhibiting the binding of C5a, thus reducing the inflammatory response and improving autoimmune disease symptoms [204]. The gene discussed is C5AR1; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.